High-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous seeding in retinoblastoma

Abstract

Purpose

To report on the use of intravitreal high-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous retinoblastoma, the toxicity of these injections, and the use of a 180-μG injection of intravitreal topotecan in humans.

Observations

High-dose (90 and 180 μG) intravitreal topotecan was effective in treating recurrent subretinal and vitreous retinoblastoma without anterior segment or retinal toxicity or altered electroretinogram function in two cases.

Conclusion and importance

Recurrent subretinal and vitreous retinoblastoma after intraarterial chemotherapy are difficult to treat. High-dose intravitreal topotecan (90 and 180 μG) was used to salvage two such eyes without measurable toxicity.